SPRB - NASDAQ

Spruce Biosciences, Inc.

Spruce Biosciences, Inc.

SPRBยทNASDAQ

$49.05

-0.22%
HealthcareBiotechnology

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$67.30M
EPS-50.8300
P/E Ratio-0.96
Earnings Date08/13/2026
Spruce Biosciences, Inc.

Spruce Biosciences, Inc. Fair Value Envelope

SPRB ยท NASDAQ

Our analysis suggests that SPRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $49.05, this represents a potential HIDDEN relative to our calculated worth for Spruce Biosciences, Inc..

HIDDEN
Intrinsic Value
Current Price: $49.05

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.9B
+ Cash & Equivalents$48.9M
Firm Value-$1.8B
- Debt$736.0K
Equity Value-$1.8B
/ Shares Outstanding563,049B
DCF Value-$3.2K
OVERVALUED BY 6629%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$46.8M
-$65.7M
-$92.3M
-$129.7M
-$182.1M
-$255.8M
-$359.3M
-$504.6M
-$708.7M
-$995.4M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$46.8M
-$65.7M
-$92.3M
-$129.7M
-$182.1M
-$255.8M
-$359.3M
-$504.6M
-$708.7M
-$995.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$43.3M
-$56.4M
-$73.3M
-$95.3M
-$124.0M
-$161.2M
-$209.6M
-$272.6M
-$354.5M
-$461.1M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your SPRB research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.